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Beside its role in motor coordination, the cerebellum is involved in cognitive function such as attention, working
memory, verbal learning, and sensory discrimination. In schizophrenia, a disturbed prefronto-thalamo-cerebellar
circuit has been proposed to play a role in the pathophysiology. In addition, a deficit in the glutamatergic N-methyl-
D-aspartate (NMDA) receptor has been hypothesized. The risk gene neuregulin 1 may play a major role in this
process. We demonstrated a higher expression of the NMDA receptor subunit 2D in the right cerebellar regions of
schizophrenia patients, which may be a secondary upregulation due to a dysfunctional receptor. In contrast, the
neuregulin 1 risk variant containing at least one C-allele was associated with decreased expression of NMDA
receptor subunit 2C, leading to a dysfunction of the NMDA receptor, which in turn may lead to a dysfunction of the
gamma amino butyric acid (GABA) system. Accordingly, from post-mortem studies, there is accumulating evidence
that GABAergic signaling is decreased in the cerebellum of schizophrenia patients. As patients in these studies are
treated with antipsychotics long term, we evaluated the effect of long-term haloperidol and clozapine treatment in
an animal model. We showed that clozapine may be superior to haloperidol in restoring a deficit in NMDA receptor
subunit 2C expression in the cerebellum. We discuss the molecular findings in the light of the role of the cerebellum
in attention and cognitive deficits in schizophrenia.
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INTRODUCTION
Schizophrenia has a worldwide prevalence of about 1%
and mainly strikes young adults between the ages of 20 and
35 years. It is a severe psychiatric disorder leading to
lifelong disability in more than 50% of sufferers and
therefore constitutes one of the 10 most costly illnesses
worldwide.
1 The course of the disease is heterogeneous with
approximately 50% of patients requiring one or more
readmissions during follow-up. Only 20% of patients will
be able to gain full employment and only 30% maintain a
stable relationship.
2
Schizophrenia has been regarded as a syndrome. In recent
decades, symptom classifications have been calculated in
four or five main domains. These include positive symp-
toms with exaggeration of normal function, such as
hallucinations, delusions, disorganized speech, and disor-
ganized behavior. The negative symptoms comprise a
diminution in mental functions, such as blunting, avolition,
alogia, and anhedonia, and a deficit in social interaction.
3,4
Besides affective symptoms (e.g., depressive mood), another
domain refers to cognitive symptoms with declarative
episodic and working memory as well as attention, which
possess special relevance for schizophrenia.
5–8 Especially
persistent cognitive deficits are very reliable predictors of a
relapse and therefore an unfavorable long-term outcome.
9,10
Further concepts of phenotypes include the appearance of
neurological soft signs such as dysdiadochokinesis or
deficits in motor coordination
11,12 and eye tracking abnorm-
alities with deficits in smooth pursuit eye movements.
13,14
However, the pathophysiology of the disease is broadly
unknown.
Pathophysiology
The dopamine hypothesis of schizophrenia postulating a
dopaminergic hyperactivity in the limbic circuitry is based
on the evidence of typical neuroleptics with a D2-dopamine
antagonism being effective in the treatment of positive
symptoms.
15 The glutamate hypothesis of schizophrenia is
based on the observation that phencyclidine and ketamine,
which block the ion channel of the glutamatergic N-methyl-
D-aspartate (NMDA) receptor and initiate NMDA hypo-
function, precipitate psychosis. This psychosis not only
models the positive symptoms of schizophrenia, but
patients even develop a chronic deteriorative psychosis that
resembles the deficit state of schizophrenia.
16,17
To date, the prevailing hypothesis of schizophrenia is that
multifactorial interactions between risk genes and environ-
mental factors impact both early and late brain develop-
mental changes. Several lines of evidence support this
neurodevelopmental hypothesis.
18 In recent years, several
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71risk genes such as dysbindin, DAOA (D-amino acid oxidase
activator), COMT (catechol-O-methyltransferase), and RSG4
and neuregulin 1 (NRG-1) have been identified, each
contributing a small amount to the risk of developing the
disease. Most of these genes such as NRG-1 are hypothe-
sized to affect the glutamatergic NMDA receptor.
19
Mutations in NRG-1 have been identified on chromosome
8p21 in schizophrenia.
19,20 In post-mortem studies, several
isoforms have been shown to be differentially expressed in
schizophrenia, possibly contributing to the pathophysiology
of the disease.
21,22
Disturbances in neuronal networks
Since the beginning of the last century, schizophrenia has
been regarded as a brain disorder. Neurotransmitter hypoth-
eses postulated disturbances in the dopaminergic and
glutamatergic system.
23,24 Structural, functional, and spectro-
scopic magnetic resonance imaging (MRI) as well as diffusion
tensor imaging studies revealed alterations in fronto-tem-
poral-thalamic-cerebellar networks including the heteromodal
association cortex and hippocampus with resulting distur-
bances in macro- and microconnectivity.
25,26 At the cellular
and molecular level, deficits in the number and function of
oligodendrocytes and myelin components as well as synaptic
proteins are prominent.
27–30 They may be related to neurode-
velopmental disturbances and, in subgroups of patients, an
additional non-typical neurodegenerative component. It has
been hypothesized that the disorder originates from brain
neurodevelopmental neuropathology with symptoms and
neuropsychological deficits arising from alterations in pre-
cisely defined brain regions or functional neuronal circuits.
31
The thalamus acts as a central relay station, transferring
peripheral sensory inputs to the cortex and receiving
projections from the cerebellum. It plays a critical role in
filtering sensory information, in regulating cognitive input to
the cortex, and in mediating corticocortical connections
between areas particularly implicated in schizophrenia, such
as the frontal and temporal regions. In schizophrenia
patients, positron emission tomography (PET) studies show
a dysfunction of the cortico-cerebellar-thalamic-cortical neu-
ronal circuit (Figure 1) contributing to ‘‘cognitive dysmetria’’,
i.e., impaired cognition and other symptoms of the dis-
ease:
32,33 the inability to receive and process information
rapidly, to retrieve the relevant associated constructs, and to
produce a well-modulated and fine-tuned response. Thus,
schizophrenia patients have subtle abnormalities of posture,
gait, emotional response and expression, and cognitive
performance.
Cerebellum and cognition: evidence from
schizophrenia
The cerebellar cortex is divided into three different cellular
layers containing five different types of glutamatergic and
gamma amino butyric acid (GABA)ergic neurons (Figure 2).
Inputs to the cerebellum are from excitatory climbing
fibers from the inferior olive and from glutamatergic
mossy fibers connecting the brainstem and cerebral cortex
with the cerebellum via the pons
34 (Figure 2). It has been
shown that, by connection via the thalamus, the cerebellum
innervates not only motor areas of the cortex, but also
prefrontal and parietal heteromodal association cortices
involved in cognition.
35 First insights revealed that the
cerebellum is known to be involved in predicting motor
control of movement outcomes.
36 After cerebellar damage,
neurocognitive symptoms and a cognitive affective syn-
drome including blunted affect and inappropriate behavior
have been shown.
37 In addition, lesions of the lateral
cerebellum impair cognitive functions including speech,
and induce mutism and amnestic aphasia. The right
cerebellum, in connection with the dorsolateral prefrontal
cortex, is involved in executive and working memory
functions, e.g., subvocal rehearsal mechanisms of verbal
working memory.
38–42
In addition, PET and functional magnetic resonance (fMRI)
studies have demonstrated the involvement of the cerebel-
lum in different cognitive tasks: sensory discrimination,
43
attention
44–46 or, more recently, the attentional part of
working memory demands,
38,47 semantic association,
48 ver-
bal learning and memory,
49 visuospatial functions,
50 and
complex problem solving.
51 The cerebellum has also been
linked to higher order cognitive control processes referred to
as executive functions.
52,53 Allthese domainsaredisturbed in
schizophrenia patients.
54 In a series of fMRI and behavioral
studies, we investigated the functional integrity of distinct
brain systems underlying maintenance-related subprocesses
of working memory (articulatory rehearsal, non-articulatory
maintenance of phonological information, maintenance of
visuospatial information) in patients with schizophrenia and
other major psychoses.
55–59 By means of circuit-specific
experimental paradigms, we were able to provide first
evidence for a possible subtype of schizophrenia with a
selective dysfunction of the articulatory subsystem of verbal
working memory, which functionally involves the cerebel-
lum.
60,61 Moreover, we were able to show that familial (and
probably also genetic) loading impacts on the functional
integrity of this articulatory rehearsal mechanism in schizo-
phrenia,
62 suggesting that selective dysfunction of this
mechanism may characterize a schizophrenia subtype with
a more homogeneous underlying pathophysiology and
genetic etiology.
60,63
Brain imaging studies of the cerebellum in
schizophrenia
In recent decades, the cerebellum has been implicated in
the pathophysiology of schizophrenia, with the cortico-
thalamo-cerebellar circuit
33 receiving particular attention.
Schizophrenia patients reveal deficits supporting impair-
ment of cerebellar functions: neurological soft signs,
Figure 1 – The connections of the cerebellum. It is projecting to
the thalamus and prefrontal cortex. Disturbances of this circuit
have been proposed to play a role in the pathophysiology of
schizophrenia.
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72dyscoordination, abnormal posture, impaired eyeblink
conditioning, procedural learning deficits, and poor cogni-
tive performance.
64 Neurological soft signs were correlated
with reduced gray matter volumes in the cerebellum and
related networks.
65,66 Structural MRI studies revealed
decreased volumes of the total cerebellum, left cerebellar
hemisphere, and right vermis,
67,68 as well as correlation of
the volume reduction with psychopathological sub-
scores.
69,70 Evidence from PET as well as fMRI studies
investigating resting state or working memory and periodic
sequence learning tasks has shown decreased activation of
cerebellar subregions.
54,67,71
1H-spectroscopic MRI studies have revealed decreased N-
acetylaspartate (NAA) and creatine in the anterior vermis
and cortex, pointing to altered neuronal integrity of
neurons, dendrites, and axons.
72,73 Reduction in NAA
indicates a loss of functional and structural integrity of
neurons, dendrites, and axons. Such neuronal dysfunction
may involve a glutamatergic deficit in the cerebellar
subregions of schizophrenic patients.
The cerebellar glutamate system and schizophrenia
An NMDA receptor hypofunction has been proposed to
play a role in schizophrenia,
24 resulting in a final hypoglu-
tamatergic state of corticostriatal projections.
24,74 The NMDA
receptor is composed of different subunits responsible for
various functional properties.
75,76 The obligate NR1 subunit
combines two or three NR2 subunits (NR2A, NR2B, NR2C,
and NR2D) to form the functional receptor. Studies using
brain tissue obtained post mortem have examined the
expression of glutamate receptor subunits, and support the
hypothesis of a glutamate dysfunction in schizophrenia.
77
In cerebellar Purkinje and Golgi neurons, all NMDA
receptor subunits are expressed
78,79 and may be altered in
schizophrenia. In the left cerebellum, a study by Akbarian et
al.
81 found no differences in NMDA receptor expression. To
determine whether NMDA receptor alteration is present in
the right and left cerebellar vermis and hemispheres in
schizophrenia, we measured NMDA receptor binding and
gene expression of the NMDA receptor subunits in a post-
mortem study of elderly patients with schizophrenia and
non-affected subjects. The results revealed a significantly
higher expression of the NR2D subunit in the right-side
anterior hemisphere and vermis compared with our group
of normal elderly control subjects. In contrast, we found no
difference in NR2D expression in the left cerebellar
subregions as well as levels of NR1, NR2A, NR2B, and
NR2C expression.
80 These results point in the same
direction as increased expression of NR2D subunit in the
left prefrontal cortex.
81 In contrast to receptors containing a
combination of NR1 with NR2A or NR2B subunits, NMDA
receptors assembled from NR1 and NR2D subunits show a
prolonged decay rate of glutamate-induced ion currents and
a lowered threshold for a voltage-dependent magnesium
blockade.
76,77 This causes ‘‘hyperexcitable’’ counteracting
reduced postsynaptic activity. Therefore, increased expres-
sion of the NR2D subunit in schizophrenic patients may be
interpreted as a secondary regulation to glutamatergic
hypoactivity in the right cerebellum.
As the expression of the NR2C subunit has been reported
to be regulated by NRG-1 maturing synapses of the
cerebellar granule cells,
82 and thus the NRG-1 risk genotype
may alter the expression or function of the NMDA receptor
in the cerebellar subregions, we genotyped the samples for
the NRG1 polymorphism rs35753505 (SNP8NRG221533).
This variant forms part of the previously reported risk
haplotype for schizophrenia, and has been described as a
tagging single nucleotide polymorphism (SNP) of the core
Figure 2 – The cerebellum contains three layers and five distinct types of neurons. Glutamatergic neurons are shown in green and
GABAergic neurons in red. In schizophrenia, a deficit in the glutamatergic NMDA receptor may lead to a GABAergic deficit and, as a
consequence, to disturbed glutamatergic projections.
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73at-risk haplotype.
19,83 Positive association findings with this
risk gene and schizophrenia and schizophrenic-related
phenotypes have been reported in several studies.
84–94 In
both groups in our post-mortem study, the NRG1
SNP8NRG221533 schizophrenia-risk genotypes containing
at least one C-allele (CC and CT) decreased gene expression
of the NR2C subunit in the molecular layer of the right
vermis and hemisphere compared with the TT genotype.
Again, on the left side, we found no genotype-specific
differences.
80 This finding was confined to the molecular
layer of the right cerebellum. Decreased expression may
lead to an NMDA receptor hypofunction, as NR2C, as a
major NMDA receptor subunit of the cerebellum, exhibits
less marked voltage-sensitive magnesium blockade and a
prolonged decay rate of glutamate-induced ion currents.
76
A deficiency in this subunit may cause decreased receptor
activation during glutamatergic stimulation and, as a
consequence, diminished synaptic sprouting. Accordingly,
in another post-mortem study, the glutamatergic synaptic
protein complexin 2 was reduced at the mRNA and protein
levels in the granule cell layer of the cerebellar cortex of
schizophrenia patients compared with healthy control
subjects,
95 supporting the hypothesis of a glutamatergic
dysfunction in schizophrenia.
Our results confirm that the cerebellum is lateralized and,
as shown in an fMRI study, the right cerebellum and the left
prefrontal cortex are both activated during a silent fluency
task in right-handed healthy subjects.
96
Alterations in the cerebellar GABAergic system and
at the cellular level
Cognitive functioning depends on the plasticity mediated,
in part, by NMDA receptors. A hypofunction of the NMDA
receptor bearing on inhibitory GABAergic interneurons
gives rise to reduced GABAergic inhibitory tone. In the long
term, these target neurons could be injured by increased
neurotransmission at ionotropic glutamatergic AMPA ((¡)-
a-amino-3-hydroxy-5-methylisoxazole-4-propionoc acid), kai-
nite, and cholinergic receptors with subsequent cell damage
and a final hypoglutamatergic state.
24,74,97 Thus, an NMDA
receptor hypofunction and a GABAergic deficit of interneur-
ons may both result in disturbed pathways at the molecular
and cellular levels. Indeed, there is evidence of impaired
interneuron function. For example, the GABA synthesizing
enzyme glutamic acid decarboxylase 67 (GAD67) and reelin,
both expressed in GABAergic interneurons, have been
reported to be downregulated at the mRNA and protein
levels in the cerebellum of schizophrenia patients.
98,99
Besides GAD67, GAD56 and the GABA transporter 1 have
been shown to be downregulated along with increased
GABAA receptor subunits, pointing to a deficit in GABAergic
neurotransmission.
100 This may be related to a deficit in the
NMDA receptor, as its antagonist phencyclidine causes
similar alterations in cerebellar Golgi cells.
101 However,
altered cell numbers of Golgi cells remain to be investigated.
In contrast, the cell density of GABAergic Purkinje neurons
has been reported to be decreased in schizophrenia patients
and heterozygous reeler mice with a deficit in reelin
expression.
102
Influence of antipsychotic treatment
As all patients involved in post-mortem studies had been
treated with antipsychotics for decades, medication effects
may have influenced the results. Accordingly, we con-
ducted an additional animal study closely investigating the
effects of a typical (haloperidol) and an atypical (clozapine)
antipsychotic medication on NMDA receptor binding and
gene expression of subunits of the NMDA receptor in
different cerebellar rat brain regions after drug administra-
tion for up to 6 months. Here, we demonstrated that
expression of NR2C was increased in clozapine-treated
animals compared with haloperidol treatment. Therefore,
clozapine may be superior to haloperidol in restoring a
deficit in NR2C expression in the right cerebellum.
80 In an
animal study of antipsychotic treatment, both haloperidol
and clozapine increased the GABAergic marker GAD67 in
the cerebellum.
100
We hypothesize that atypical antipsychotics may restore
brain function by influencing the glutamatergic system and
consecutive changes in neuroplasticity and brain activa-
tion. For example, antipsychotics are known to influence
gray matter volumes in the cortex and, after 8 weeks of
treatment, a volume increase has been found in the
bilateral cerebellum as well.
103 A recent fMRI study during
saccades to visual targets revealed less activation of the
cerebellum and related networks in antipsychotic-naı ¨ve
first-episode schizophrenia patients and the restoring
effects of subchronic treatment with the atypical antipsy-
chotic risperidone.
104 During presentation of pictures of
facial emotions of happy faces, risperidone activated the
right cerebellum compared with treatment with typical
neuroleptics, suggesting superior effects of atypical anti-
psychotics.
105 As a glutamatergic deficit in the cerebellum
may contribute to cognitive symptoms in the disease,
medication with glutamate agonists may be beneficial in
chronic schizophrenia.
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